Valuation: VolitionRx Limited

Market Cap 2.62M 2.37M 2.19M 1.98M 3.74M 246M 3.85M 26.25M 10.43M 132M 9.83M 9.62M 419M P/E 2026 *
-0.09x
P/E 2027 * -0.18x
Enterprise Value 2.62M 2.37M 2.19M 1.98M 3.74M 246M 3.85M 26.25M 10.43M 132M 9.83M 9.62M 419M EV / Sales 2026 *
0.96x
EV / Sales 2027 * 0.28x
Free-Float
94.07%
Yield 2026 *
-
Yield 2027 * -
1 day-9.38%
1 week-2.38%
Current month-5.53%
1 month-9.16%
3 months-72.41%
6 months-92.05%
Current year-96.39%
1 week 0.18
Extreme 0.1782
0.21
1 month 0.16
Extreme 0.1564
0.22
Current year 0.16
Extreme 0.1564
7.73
1 year 0.16
Extreme 0.1564
7.73
3 years 0.16
Extreme 0.1564
24.6
5 years 0.16
Extreme 0.1564
82.8
10 years 0.16
Extreme 0.1564
136.8
Manager TitleAgeSince
Chief Executive Officer 55 06/10/2011
Director of Finance/CFO 56 01/02/2021
Chief Tech/Sci/R&D Officer 49 01/04/2024
Director TitleAgeSince
Director/Board Member 55 06/10/2011
Director/Board Member 77 06/10/2011
Director/Board Member 64 09/10/2019
Date Insider Type Main position Quantity % Market Cap. Importance
21/10/26 Free

Public Communications Manager

12,000 0.0430%
28/9/26 Tax

Executive/Senior Manager

-284 0.0010%
28/9/26 Tax

Chief Operating Officer

-608 0.0022% -
Change 5-day change 1-year change 3-year change Capi.($)
-9.38%-2.38%-97.51%-98.95% 2.62M
+1.10%-2.67%+62.79%+70.47% 68.45B
+0.77%+9.54%+16.23%+94.22% 61.31B
+0.08%+0.48%+20.63%+98.63% 55.73B
-0.96%+7.41%+10.20%+108.91% 47.51B
-1.25%+2.35%+22.74%+38.34% 44.68B
-2.41%-0.73%+167.89%+794.72% 38.14B
+1.21%-2.56%+20.27%+52.81% 35.85B
-1.01%-1.05%+77.65%+54.56% 33.05B
-2.22%+8.56%-39.26%+397.14% 25.9B
Average -1.41%+2.16%+26.16%+161.08% 41B
Weighted average by Cap. -0.28%+2.84%+40.48%+163.85%

Financials

2026 *2027 *
Net sales 2.72M 2.46M 2.27M 2.06M 3.88M 256M 4M 27.29M 10.84M 137M 10.22M 10M 436M 9.27M 8.39M 7.74M 7.01M 13.22M 872M 13.62M 92.92M 36.93M 466M 34.81M 34.07M 1.48B
Net income -22.25M -20.12M -18.57M -16.81M -31.72M -2.09B -32.68M -223M -88.6M -1.12B -83.51M -81.73M -3.56B -18.42M -16.66M -15.37M -13.92M -26.26M -1.73B -27.05M -185M -73.34M -926M -69.13M -67.65M -2.95B
Net Debt - -
Projected Income Statement - Annual - VolitionRx Limited
Logo VolitionRx Limited
VolitionRx Limited is a company focused on advancing the science of epigenetics. The Company is focused on saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its products are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
57
Date Price Change Volume
12/11/26 USD 0.1845 -9.38% 995,894
11/11/26 USD 0.2036 +10.41% 681,852
10/11/26 USD 0.1844 -7.80% 757,965
09/11/26 USD 0.2000 +2.09% 401,469
06/11/26 USD 0.1959 +3.65% 468,083
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - VolitionRx Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.1845USD
Average target price
13.62USD
Spread / Average Target
+7,283.20%
  1. Stock Market
  2. Stocks
  3. VNRX Stock